Metabolic Markers and HSP60 in Chemonaive Serous Solid Ovarian Cancer Versus Ascites

Hjerpe, Elisabet; Brage, Suzanne Egyházi; Stolt, Marianne Frostvik; Johansson, Hemming; Shoshan, Maria C.; Åvall‐Lundqvist, Elisabeth

doi:10.1097/igc.0000000000000246

Cited by 7 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data in this study are derived from a small pilot study, but is representative of our institutional clinical practice in regard to OC histology and stage distribution as well as published pilot studies examining IL-1β in urine, serum, and plasma [17,56,[58][59][60][61] and other clinically relevant pilot studies [62][63][64][65][66]. A normal baseline value for urinary IL-1β in women has not yet been established in the literature [67].…”

Section: Discussionmentioning

confidence: 99%

Urinary interleukin-1ß levels among gynecological patients

Woolery

Hoffman

Kraft

et al. 2014

Journal of Ovarian Research

View full text Add to dashboard Cite

Background: Early detection of epithelial ovarian cancer (OC) is necessary to overcome the high mortality rate of late stage diagnosis; and, examining the molecular changes that occur at early disease onset may provide new strategies for OC detection. Since the deregulation of inflammatory mediators can contribute to OC development, the purpose of this pilot study was to determine whether elevated urinary levels of Interleukin-1beta (IL-1 beta) are associated with OC and associated clinical parameters. Methods: Urinary and serum levels of IL-1 beta were analyzed by ELISA from a patient cohort consisting of healthy women (N = 10), women with ovarian benign disease (N = 23), women with OC (N = 32), women with other benign gynecological conditions (N = 22), and women with other gynecological cancers (N = 6). Results: Average urinary IL-1 beta levels tended to be elevated in ovarian benign (1.26 pg/ml) and OC (1.57 pg/ml) patient samples compared to healthy individuals (0.36 pg/ml). Among patients with benign disease, urinary IL-1β levels were statistically higher in patients with benign inflammatory gynecologic disease compared to patients with non-inflammatory benign disease. Interestingly, urinary IL-1 beta levels tended to be 3-6x greater in patients with benign ovarian disease or OC as well as with a concomitant family history of ovarian and/or breast cancer compared to similar patients without a family history of ovarian and/or breast cancer. Lastly, there was a pattern of increased urinary IL-1 beta with increasing body mass index (BMI); patients with a normal BMI averaged urinary IL-1 beta levels of 0.92 pg/ml, overweight BMI averaged urinary IL-1 beta levels of 1.72 pg/ml, and obese BMI averaged urinary IL-1 beta levels of 5.26 pg/ml. Conclusions: This pilot study revealed that urinary levels of IL-1 beta are elevated in patients with epithelial OC supporting the thought that inflammation might be associated with cancer progression. Consequently, further studies of urinary IL-1 beta and the identification of an inflammatory profile specific to OC development may be beneficial to reduce the mortality associated with this disease.

show abstract